MDGL - Madrigal Pharmaceuticals, Inc.
99.00 -0.08 (-0.08%)
After hours: 4:36PM EST
| Previous Close | 118.50 |
| Open | 104.63 |
| Bid | 99.32 x 3100 |
| Ask | 99.65 x 1100 |
| Day's Range | 98.66 - 104.63 |
| 52 Week Range | 82.31 - 148.18 |
| Volume | 1596656 |
| Avg. Volume | 152,003 |
| Market Cap | 1.5B |
| Beta (3Y Monthly) | 1.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.40 |
| Earnings Date | Nov 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 183.67 |
- GlobeNewswire
Madrigal Pharmaceuticals Announces Pricing of Secondary Offering
In connection with the offering, the selling stockholders have granted the underwriter an option, exercisable for 30 days after December 10, 2019, to purchase up to 180,000 additional shares of common stock, at the public offering price, less underwriting discounts, from the selling stockholders. The offering is expected to close on or about December 13, 2019, subject to the satisfaction of customary closing conditions.
- GlobeNewswire
Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock
CONSHOHOCKEN, Pa., Dec. 10, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the.
- Zacks
NASH Scorecard Year to Date: The Winners and the Losers
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
- GlobeNewswire
Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)
Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH: demonstrated that resmetirom treatment resulted.
- GlobeNewswire
Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights
CONSHOHOCKEN, Pa., Nov. 06, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights: “Madrigal continued.
- Insider Monkey
Hedge Funds Are Dumping Madrigal Pharmaceuticals, Inc. (MDGL)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)?
If you own shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) then it's worth thinking about how it contributes to...
- GlobeNewswire
Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights
-- Phase 3 MAESTRO-NASH Program Continues to Progress -- -- Jim Daly Added to Board of Directors and Becky Taub Promoted to President of R&D -- -- Madrigal.
- GlobeNewswire
Madrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development
Madrigal Pharmaceuticals, Inc. (MDGL) announced today the promotion of Rebecca Taub, M.D., to the newly created positon of President of Research & Development. Dr. Taub has served as Chief Medical Officer and Executive Vice President of Research & Development, of Madrigal since 2016.
- Simply Wall St.
Have Insiders Been Buying Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- GlobeNewswire
Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors
Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of Acadia Pharmaceuticals, argenx SE, Bellicum Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc. Most recently, Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. Previously, Mr. Daly worked for Amgen, Inc. and held various leadership positions over a 10-year period, including his last role as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier in his career, he spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including his last role as Senior Vice President, General Manager of the Respiratory and Anti-Infective Business Unit.
- Insider Monkey
Here’s What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL)
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]
GuruFocus.com2 Falling Knives With No Debt
Warning! GuruFocus has detected 3 Warning Signs with IRDM. The risk is very high with this kind of investment, but if investors look for companies that have no debt and a moderate to high current ratio, the risk can be significantly decreased. In addition, the companies have received an overweight recommendation rating from Wall Street, increasing the chances of a successful bet as these stocks are expected to outperform their industries within 12 months.
- GlobeNewswire
Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences
CONSHOHOCKEN, Pa., June 04, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Paul Friedman, M.D., Chief Executive Officer of Madrigal, and Becky Taub,.
- GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of Madrigal Pharmaceuticals, Inc.
NEW YORK, May 15, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Madrigal Pharmaceuticals, Inc. (NASDAQCM: MDGL) concerning possible breaches of.
- Simply Wall St.
If You Had Bought Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock A Year Ago, You'd Be Sitting On A 12% Loss, Today
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The simplest way to benefit from a rising market is to buy an index fund. But if you buy individ...
- Associated Press
Madrigal: 1Q Earnings Snapshot
On a per-share basis, the West Conshohocken, Pennsylvania-based company said it had a loss of 98 cents. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...
- GlobeNewswire
Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights
CONSHOHOCKEN, Pa., May 08, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2019 financial results and highlights: “Madrigal continued to.
- Insider Monkey
Is Madrigal Pharmaceuticals, Inc. (MDGL) A Good Stock To Buy?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth […]
- GlobeNewswire
Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019
-- MRI-PDFF response (≥30% reduction in hepatic fat) at 12 weeks correlated with reduction in the ballooning and inflammation components of NAS and was predictive of NASH.
- Motley Fool
Here's Why Investors Are Betting Against These 2 Biotech Stocks
Are intrepid short-sellers taking advantage of misguided enthusiasm?
- GlobeNewswire
Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
Madrigal Pharmaceuticals, Inc. (MDGL) announced today that it has initiated its Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, MGL-3196 (resmetirom). This double-blind, placebo-controlled study will be conducted at more than 150 sites in the United States and the rest of the world.
- Zacks
Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus
Intercept's (ICPT) Q4 revenues top estimates owing to strong Ocaliva sales, driven by sales force expansion and growth in its foreign geographies.
- Motley Fool
Is Viking Therapeutics a Buy?
Once sky-high stocks of pharmaceutical companies pursing treatments for NASH have gotten a lot cheaper, especially this one.
- Simply Wall St.
All You Need To Know About Madrigal Pharmaceuticals, Inc.’s (NASDAQ:MDGL) Financial Health
Mid-caps stocks, like Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) with a market capitalization of US$2.1b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
